最新ニュース Atari (OTC:PONGF) 株価情報

Atari SA is in the electronic gaming and multimedia business sector. It is engaged in the design, production, publishing, and distribution of all multimedia and audiovisual products and works, including those like entertainment, in any form including software, data processing, and content. The group has four lines of business Games, Hardware, Licensing, and Blockchain. It owns and manages a portfolio of more than four hundred special games and franchises, including world-renowned brands like Pong, Breakout, Asteroids, Missile Command, Centipede, and RollerCoaster Tycoon. The company provides various types of gaming which include a mobile and online arcade. Mobile gaming consists of Goon Squad, roller coaster tycoon, haunted house, pong world, circus Atari, centipede, breakout, and others.

Atari SA

<p>Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) reported quarterly losses of $(1.61) per share. This is a 30.89 percent decrease over losses of $(1.23) per share from the same period last year.  The company reported $1.01 million in sales this quarter. This is a 83.42 percent increase over sales of $549.00 thousand the same period last year.</p>


Earnings

News

BZAI

Blaize Holdings Q1 EPS $(1.61) Down From $(1.23) YoY, Sales $1.01M Up From $549.00K YoY

<p><i>–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated</i></p>
<p><i>–Oveporexton Found to be Generally Safe and Well Tolerated</i></p>
<p><i>–Phase 3 Readout of Oveporexton Anticipated in 2025</i></p>


Biotech

General

Takeda Pharmaceutical Data From Phase 2b Trial Of Oveporexton In People With Narcolepsy Type 1 Published In New England Journal Of Medicine

<p>GameSquare Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAME#NASDAQ">GAME</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-15. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that GameSquare Holdings will report an <strong>earnings per share</strong> (EPS) of $-0.09.</p>
<p>GameSquare Holdings bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS missed by $0.73 in the last quarter, leading to a 5.88% drop in the share price on the following day.</p>
<p>Here's a look at GameSquare Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.08</td>
<td>-0.14</td>
<td>-0.09</td>
<td>-0.29</td>
<td>-0.23</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.81</td>
<td>-0.15</td>
<td>-0.38</td>
<td>-0.39</td>
<td>-1.37</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>-15.0%</td>
<td>4.0%</td>
<td>1.0%</td>
<td>-27.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747256628_0.png" alt="eps graph" /></p>
<h3>Tracking GameSquare Holdings's Stock Performance</h3>
<p>Shares of GameSquare Holdings were trading at $0.6239 as of May 13. Over the last 52-week period, shares are down 53.65%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GAME/earnings"><strong>To track all earnings releases for GameSquare Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GAME

A Look Ahead: GameSquare Holdings's Earnings Forecast

<p>Reliance Global Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) reported quarterly losses of $(0.66) per share. This is a 95.21 percent increase over losses of $(13.77) per share from the same period last year.  The company reported $4.24 million in sales this quarter. This is a 3.77 percent increase over sales of $4.08 million the same period last year.</p>


RELI

Reliance Global Group Q1 EPS $(0.66) Up From $(13.77) YoY, Sales $4.24M Up From $4.08M YoY

<p>American Shared Hospital (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMS#AMEX">AMS</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-15. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that American Shared Hospital will report an <strong>earnings per share</strong> (EPS) of $0.04.</p>
<p>Anticipation surrounds American Shared Hospital's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company missed EPS by $0.21, leading to a 0.0% drop in the share price the following trading session.</p>
<p>Here's a look at American Shared Hospital's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.01</td>
<td>0.08</td>
<td>0.07</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.20</td>
<td>-0.03</td>
<td>0.02</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>8.0%</td>
<td>-3.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747256613_0.png" alt="eps graph" /></p>
<h3>Tracking American Shared Hospital's Stock Performance</h3>
<p>Shares of American Shared Hospital were trading at $2.85 as of May 13. Over the last 52-week period, shares are down 10.51%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/AMS/earnings"><strong>To track all earnings releases for American Shared Hospital visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Examining the Future: American Shared Hospital's Earnings Outlook

<p><strong>DXC Technology Co. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) released its fourth-quarter results after Wednesday's closing bell. Here's a look at the key figures<a href="https://www.benzinga.com/pressreleases/25/05/b45420485/dxc-technology-reports-fourth-quarter-and-full-year-fiscal-2025-results"> from the quarter. </a></p>
<p><strong>The Details: </strong>DXC Technology reported quarterly earnings of 84 cents per share, which beat the consensus estimate of 77 cents. Quarterly revenue clocked in at $3.17 billion, which beat the Street estimate of $3.13 billion.</p>
<p><strong>Read Next: </strong><a href="https://www.benzinga.com/news/large-cap/25/05/45414265/nvidia-climbs-on-saudi-ai-investments-analyst-estimates-15-billion-to-20-billion-in-revenue?utm_source=articleShare"><strong>Nvidia Climbs On Saudi AI Investments: Analyst Estimates $15 Billion To $20 Billion In Revenue&nbsp;</strong></a></p>
<p>&#8220;Our fourth quarter results represent continued progress toward our goal of achieving sustained, profitable revenue growth,&#8221; said DXC Technology CEO <strong>Raul Fernandez</strong>.</p>
<p>&#8220;For the second consecutive quarter, we reported bookings growth of more than 20% and book to bill ratios of greater than 1. While the macro backdrop remains uncertain, we&#8217;re staying focused on our priorities, delivering our deep and broad capabilities to our customers, driving performance with a newly energized and engaged employee base, and continuing to build a culture of accountability, collaboration and urgency,&#8221; Fernandez said.</p>
<p><strong>Outlook: </strong>DXC Technology sees first-quarter adjusted EPS of between 55 cents and 65 cents per share, versus the 77 cent analyst estimate, and revenue in a range of $3.04 billion to $3.09 billion, versus the $3.12 billion estimate.</p>
<p>DXC sees fiscal 2026 adjusted EPS of&nbsp;between $2.75 and $3.25, versus the $3.41&nbsp;analyst estimate, revenue in a range of $12.18 billion to $12.44 billion, versus the&nbsp;$12.41 billion&nbsp;estimate.</p>
<p><strong>DXC Price Action:</strong> According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, DXC Technology stock was down 13.04% at $14.40 after-hours Wednesday.  </p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45353123/quantum-stocks-are-hot-in-2025-biggest-movers-to-watch?utm_source=articleShare"><strong>Quantum Stocks Are Hot In 2025: Biggest Movers To Watch&nbsp;</strong></a></li>
</ul>
<p><em>Image: Shutterstock</em></p>


After-Hours Center

Movers

Tech

DXC Technology Stock Drops After Q4 Results, Q1 Guidance Below Estimates

<p><strong>Bridgeline Digital</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIN#NASDAQ">BLIN</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-15. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Bridgeline Digital will report an <strong>earnings per share</strong> (EPS) of $0.00. </p>
<p>Investors in Bridgeline Digital are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company missed EPS by $0.01, which was followed by a 11.62% drop in the share price the next day.</p>
<p>Here's a look at Bridgeline Digital's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.05</td>
<td>-0.01</td>
<td>-0.04</td>
<td>-0.02</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.06</td>
<td>0</td>
<td>0</td>
<td>-0.02</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-12.0%</td>
<td>-14.000000000000002%</td>
<td>5.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747256605_0.png" alt="eps graph" /></p>
<h3>Market Performance of Bridgeline Digital's Stock</h3>
<p>Shares of Bridgeline Digital were trading at $1.86 as of May 13. Over the last 52-week period, shares are up 67.13%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BLIN/earnings"><strong>To track all earnings releases for Bridgeline Digital visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BLIN

Examining the Future: Bridgeline Digital's Earnings Outlook

PRPO

Precipio Q1 EPS $(0.59) Up From $(1.46) YoY, Sales $4.93M Up From $3.43M YoY

<p>Fluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNT#NASDAQ">FLNT</a>) will release its quarterly earnings report on Thursday, 2025-05-15. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Fluent to report an <strong>earnings per share</strong> (EPS) of $-0.26.</p>
<p>The announcement from Fluent is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.05, which was followed by a 0.0% drop in the share price the next day.</p>
<p>Here's a look at Fluent's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.23</td>
<td>-0.08</td>
<td>-0.30</td>
<td>-0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.18</td>
<td>-0.22</td>
<td>-0.47</td>
<td>-0.30</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-7.000000000000001%</td>
<td>-10.0%</td>
<td>-13.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747256594_0.png" alt="eps graph" /></p>
<h3>Performance of Fluent Shares</h3>
<p>Shares of Fluent were trading at $2.41 as of May 13. Over the last 52-week period, shares are down 31.88%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analysts' Take on Fluent</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Fluent.</p>
<p>Analysts have provided Fluent with 1 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $3.5, suggesting a potential 45.23% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of  and Fluent, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<h3>Insights: Peer Analysis</h3>
<p>Within the peer analysis summary, vital metrics for  and Fluent are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluent</td>
<td>Neutral</td>
<td>-10.11%</td>
<td>$13.90M</td>
<td>-15.27%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Fluent ranks at the bottom among peers in terms of consensus sentiment. It also shows the lowest revenue growth rate compared to peers. Additionally, its gross profit margin is the lowest in the group. Furthermore, Fluent's return on equity is the weakest among its peers.</p>
<h3>Unveiling the Story Behind Fluent</h3>
<p>Fluent Inc is a data-driven digital marketing services company. It performs customer acquisition services by operating digital marketing campaigns, through which it connects its advertiser clients with consumers company is seeking to reach. It delivers data and performance-based marketing executions to its clients, such as consumer brands, direct marketers and agencies across a wide range of industries, including Financial Products &amp; Services, Media &amp; Entertainment, Health &amp; Wellness, Staffing &amp; Recruitment and Retail &amp; Consumer.</p>
<h3>Fluent: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Fluent's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-10.11%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Communication Services sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Fluent's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-5.24%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Fluent's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-15.27%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-3.62%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.5</strong>, Fluent faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/FLNT/earnings"><strong>To track all earnings releases for Fluent visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


FLNT

Uncovering Potential: Fluent's Earnings Preview

<p><strong>VolitionRX</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-15. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that VolitionRX will report an <strong>earnings per share</strong> (EPS) of $-0.04. </p>
<p>The market awaits VolitionRX's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.01, leading to a 9.03% drop in the share price on the subsequent day.</p>
<p>Here's a look at VolitionRX's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.05</td>
<td>-0.07</td>
<td>-0.09</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.06</td>
<td>-0.07</td>
<td>-0.08</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-9.0%</td>
<td>-6.0%</td>
<td>3.0%</td>
<td>-15.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747256582_0.png" alt="eps graph" /></p>
<h3>VolitionRX Share Price Analysis</h3>
<p>Shares of VolitionRX were trading at $0.4678 as of May 13. Over the last 52-week period, shares are down 41.17%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/VNRX/earnings"><strong>To track all earnings releases for VolitionRX visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


VNRX

VolitionRX Earnings Preview

<p><strong>P3 Health Partners</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-15. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that P3 Health Partners will report an <strong>earnings per share</strong> (EPS) of $-0.10. </p>
<p>Investors in P3 Health Partners are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.22, leading to a 4.59% drop in the share price the following trading session.</p>
<p>Here's a look at P3 Health Partners's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.17</td>
<td>-0.04</td>
<td>-0.05</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.39</td>
<td>-0.31</td>
<td>-0.15</td>
<td>-0.16</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>-36.0%</td>
<td>-4.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747256553_0.png" alt="eps graph" /></p>
<h3>Tracking P3 Health Partners's Stock Performance</h3>
<p>Shares of P3 Health Partners were trading at $8.19 as of May 09. Over the last 52-week period, shares are down 72.74%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Opinions on P3 Health Partners</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on P3 Health Partners.</p>
<p>Analysts have provided P3 Health Partners with 1 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $20.0, suggesting a potential 144.2% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Biodesix, DocGo and AirSculpt Technologies, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Biodesix, with an average 1-year price target of $1.88, suggesting a potential 77.05% downside.</li>
<li>Analysts currently favor an Buy trajectory for DocGo, with an average 1-year price target of $3.59, suggesting a potential 56.17% downside.</li>
<li>Analysts currently favor an Neutral trajectory for AirSculpt Technologies, with an average 1-year price target of $2.5, suggesting a potential 69.47% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Biodesix, DocGo and AirSculpt Technologies, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vivos Therapeutics</td>
<td>Buy</td>
<td>13.85%</td>
<td>$2.10M</td>
<td>-36.20%</td>
</tr>
<tr>
<td>Biodesix</td>
<td>Buy</td>
<td>39.28%</td>
<td>$16.09M</td>
<td>-33.86%</td>
</tr>
<tr>
<td>DocGo</td>
<td>Buy</td>
<td>-50.01%</td>
<td>$30.85M</td>
<td>-2.98%</td>
</tr>
<tr>
<td>AirSculpt Technologies</td>
<td>Neutral</td>
<td>-17.32%</td>
<td>$23.42M</td>
<td>-3.64%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>P3 Health Partners ranks at the top for Revenue Growth among its peers. It is at the bottom for Gross Profit and Return on Equity. The Consensus rating for P3 Health Partners is not provided in the data.</p>
<h3>Get to Know P3 Health Partners Better</h3>
<p>P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.</p>
<h3>Understanding the Numbers: P3 Health Partners's Finances</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining P3 Health Partners's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>6.87%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> P3 Health Partners's net margin excels beyond industry benchmarks, reaching <strong>-15.81%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-59.68%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> P3 Health Partners's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-7.25%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.19</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/PIII/earnings"><strong>To track all earnings releases for P3 Health Partners visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PIII

What to Expect from P3 Health Partners's Earnings

<p>Carbon Revolution (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) reported quarterly losses of $(77.90) per share.  The company reported $47.34 million in sales this quarter. This is a 87.09 percent increase over sales of $25.30 million the same period last year.</p>


CREV

Carbon Revolution FY EPS $(77.90), Sales $47.34M Up From $25.30M YoY

<p>Cango (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) reported quarterly losses of $(0.28) per share. This is a 333.33 percent decrease over earnings of $0.12 per share from the same period last year.  The company reported $145.23 million in sales this quarter. This is a 1.53K percent increase over sales of $8.92 million the same period last year.</p>


CANG

Cango Q1 GAAP EPS $(0.28) Down From $0.12 YoY, Sales $145.23M Up From $8.92M YoY

<p>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) will release its quarterly earnings report on Thursday, 2025-05-15. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Lantern Pharma to report an <strong>earnings per share</strong> (EPS) of $-0.49.</p>
<p>The announcement from Lantern Pharma is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.03, leading to a 4.57% drop in the share price on the subsequent day.</p>
<p>Here's a look at Lantern Pharma's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.51</td>
<td>-0.56</td>
<td>-0.55</td>
<td>-0.43</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.54</td>
<td>-0.42</td>
<td>-0.46</td>
<td>-0.51</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>12.0%</td>
<td>-8.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747256541_0.png" alt="eps graph" /></p>
<h3>Performance of Lantern Pharma Shares</h3>
<p>Shares of Lantern Pharma were trading at $4.11 as of May 12. Over the last 52-week period, shares are down 33.88%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LTRN/earnings"><strong>To track all earnings releases for Lantern Pharma visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LTRN

Lantern Pharma's Earnings Outlook

<p>Rewalk Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFWD#NASDAQ">LFWD</a>) will release its quarterly earnings report on Thursday, 2025-05-15. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Rewalk Robotics to report an <strong>earnings per share</strong> (EPS) of $-0.33.</p>
<p>Rewalk Robotics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $0.13, leading to a 0.0% drop in the share price the following trading session.</p>
<p>Here's a look at Rewalk Robotics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.51</td>
<td>-0.31</td>
<td>-0.55</td>
<td>-0.70</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.38</td>
<td>-0.45</td>
<td>-0.42</td>
<td>-0.62</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>-16.0%</td>
<td>-9.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747256523_0.png" alt="eps graph" /></p>
<h3>Tracking Rewalk Robotics's Stock Performance</h3>
<p>Shares of Rewalk Robotics were trading at $1.42 as of May 13. Over the last 52-week period, shares are down 71.54%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LFWD/earnings"><strong>To track all earnings releases for Rewalk Robotics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LFWD

Examining the Future: Rewalk Robotics's Earnings Outlook

<p><strong>Super League Enterprise</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-15. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Super League Enterprise will report an <strong>earnings per share</strong> (EPS) of $-0.33. </p>
<p>Investors in Super League Enterprise are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $0.02, leading to a 0.0% drop in the share price the following trading session.</p>
<p>Here's a look at Super League Enterprise's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.31</td>
<td>-0.31</td>
<td>-0.67</td>
<td>-1.14</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.29</td>
<td>-0.25</td>
<td>-0.43</td>
<td>-0.64</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-33.0%</td>
<td>-23.0%</td>
<td>-3.0%</td>
<td>-17.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747256516_0.png" alt="eps graph" /></p>
<h3>Performance of Super League Enterprise Shares</h3>
<p>Shares of Super League Enterprise were trading at $0.15 as of May 13. Over the last 52-week period, shares are down 87.78%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SLE/earnings"><strong>To track all earnings releases for Super League Enterprise visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Peek at Super League Enterprise's Future Earnings

<p><strong>Duos Technologies Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOT#NASDAQ">DUOT</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-15. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Duos Technologies Group will report an <strong>earnings per share</strong> (EPS) of $0.17. </p>
<p>The announcement from Duos Technologies Group is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.12, leading to a 7.45% drop in the share price the following trading session.</p>
<p>Here's a look at Duos Technologies Group's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.29</td>
<td>-0.25</td>
<td>-0.33</td>
<td>-0.38</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.41</td>
<td>-0.23</td>
<td>-0.43</td>
<td>-0.38</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>13.0%</td>
<td>-3.0%</td>
<td>14.000000000000002%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747256499_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Duos Technologies Group were trading at $7.47 as of May 13. Over the last 52-week period, shares are up 163.64%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Analysts' Take on Duos Technologies Group</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Duos Technologies Group.</p>
<p>With 1 analyst ratings, Duos Technologies Group has a consensus rating of Buy. The average one-year price target is $9.0, indicating a potential 20.48% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Alarum Technologies, Silvaco Group and Intrusion, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Alarum Technologies, with an average 1-year price target of $11.0, suggesting a potential 47.26% upside.</li>
<li>Analysts currently favor an Buy trajectory for Silvaco Group, with an average 1-year price target of $15.25, suggesting a potential 104.15% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Intrusion, with an average 1-year price target of $1.25, suggesting a potential 83.27% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary outlines pivotal metrics for Alarum Technologies, Silvaco Group and Intrusion, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duos Technologies Group</td>
<td>Buy</td>
<td>-4.27%</td>
<td>$-329.95K</td>
<td>-142.71%</td>
</tr>
<tr>
<td>Alarum Technologies</td>
<td>Buy</td>
<td>3.70%</td>
<td>$5.34M</td>
<td>1.72%</td>
</tr>
<tr>
<td>Silvaco Group</td>
<td>Buy</td>
<td>-11.31%</td>
<td>$11.08M</td>
<td>-20.99%</td>
</tr>
<tr>
<td>Intrusion</td>
<td>Neutral</td>
<td>56.94%</td>
<td>$1.34M</td>
<td>-26.52%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Duos Technologies Group ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages indicating a decline. The company also has the lowest Return on Equity among its peers. In contrast, it is not the worst performer for Consensus rating, but still falls below the top.</p>
<h3>Delving into Duos Technologies Group's Background</h3>
<p>Duos Technologies Group Inc operating under its brand name duostech, designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics and intermodal businesses that streamline operations, improve safety and reduce costs. The company's main offering, the Railcar Inspection Portal (RIP), provides both freight and transit railroad customers and select government agencies the ability to conduct fully automated railcar inspections of trains that are moving at full speed. It has also developed the Automated Logistics Information System (ALIS) which automates gatehouse operations where transport trucks enter and exit large logistics and intermodal facilities. Its segments are Rail, Commercial, Governments, Banking and AI.</p>
<h3>Understanding the Numbers: Duos Technologies Group's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Duos Technologies Group's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-4.27%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Duos Technologies Group's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-233.18%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Duos Technologies Group's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-142.71%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Duos Technologies Group's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-11.96%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Duos Technologies Group's debt-to-equity ratio is below the industry average at <strong>3.77</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/DUOT/earnings"><strong>To track all earnings releases for Duos Technologies Group visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


DUOT

Duos Technologies Group Earnings Preview

<p>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) will release its quarterly earnings report on Thursday, 2025-05-15. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Mersana Therapeutics to report an <strong>earnings per share</strong> (EPS) of $-0.19.</p>
<p>The market awaits Mersana Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.04, which was followed by a 5.9% increase in the share price the next day.</p>
<p>Here's a look at Mersana Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.15</td>
<td>-0.17</td>
<td>-0.17</td>
<td>-0.18</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.11</td>
<td>-0.09</td>
<td>-0.20</td>
<td>-0.16</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>-4.0%</td>
<td>-9.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747256491_0.png" alt="eps graph" /></p>
<h3>Tracking Mersana Therapeutics's Stock Performance</h3>
<p>Shares of Mersana Therapeutics were trading at $0.3582 as of May 13. Over the last 52-week period, shares are down 85.27%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MRSN/earnings"><strong>To track all earnings releases for Mersana Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MRSN

An Overview of Mersana Therapeutics's Earnings

Management

Waste Management Appoints John Morris As President

<p>During the last three months, 10 analysts shared their evaluations of Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $175.6, a high estimate of $230.00, and a low estimate of $137.00. This current average reflects an increase of 3.83% from the previous average price target of $169.12. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747256471_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Tenet Healthcare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$154.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$189.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$137.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$165.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Tenet Healthcare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Tenet Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Tenet Healthcare's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/THC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Tenet Healthcare analyst ratings.</strong></a></p>
<h2>Get to Know Tenet Healthcare Better</h2>
<p>Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.</p>
<h3>Tenet Healthcare: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Tenet Healthcare's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately <strong>-2.7%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Tenet Healthcare's net margin excels beyond industry benchmarks, reaching <strong>7.77%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Tenet Healthcare's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>9.72%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Tenet Healthcare's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.4%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Tenet Healthcare's debt-to-equity ratio is below the industry average. With a ratio of <b>3.15</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

Atari

ニュース

最新ニュース Atari (OTC:PONGF) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル